EC Nutrition

Introduction: The intricate interplay between gut microbiota and mood disturbances, specifically Major Depressive Disorder (MDD), is currently being updated.

Objective: To investigate the involvement of the gut-brain-microbiota axis in Major Depressive Disorder (MDD) and assess the potential of probiotics as a viable therapeutic option.

Methods: A comprehensive review of Spanish and English literature on the topic was conducted using Google Scholar, PubMed, SciELO and Web of Science databases from 2019 to 2023.

Results: The relationship between gut microbiota and Major Depressive Disorder (MDD) was explored. Bidirectional communication between gut microbiota and the brain can impact depressive symptoms. Individuals with MDD exhibited alterations in their microbiota composition, characterized by reduced beneficial bacteria and increased pro-inflammatory bacteria. Probiotics are being investigated as a complementary therapy for MDD, showing promising results, although further studies are needed.

Conclusion: This article delves into the potential use of probiotics as a complementary therapy for Major Depressive Disorder (MDD). While preclinical studies have shown encouraging outcomes concerning the benefits of probiotics in enhancing gut function and reducing inflammation, further research in this field is required.

 Keywords: Microbiome; Gut Microbiota; Gut-Brain-Microbiota Axis; Dysbiosis; Major Depressive Disorder; Depression; Probiotics

1. DSM-5-TR^® Manual Diagnóstico y Estadístico de los Trastornos Mentales. Revised text. Editorial Médica Panamericana (2023).
2. Moreno-Agostino D., et al. “Global trends in the prevalence and incidence of depression:a systematic review and meta-analysis”. Journal of Affective Disorders 281 (2021): 235-243.
3. Schildkraut JJ. “The catecholamine hypothesis”. In: The Psychopharmacologists III. CRC Press (2020): 111-134.
4. Dobrek L and Głowacka K. “Depression and its phytopharmacotherapy-A narrative review”. International Journal of Molecular Sciences5 (2023).
5. Hu Y., et al. “Etiology of depression: Biological and environmental factors in the development of depression”. International Dental Journal of Student's Research4 (2021).
6. Yang Q., et al. “Gut microbiome and poultry health”. In: Gut Microbiota, Immunity, and Health in Production Animals. Cham: Springer International Publishing (2022): 69-84.
7. Thriene K and Michels KB. “Human Gut Microbiota Plasticity throughout the Life Course”. International Journal of Environmental Research and Public Health2 (2023).
8. Olsson LM., et al. “Dynamics of the normal gut microbiota: A longitudinal one-year population study in Sweden”. Cell Host Microbe5 (2022): 726-739.e3.
9. Sanada K., et al. “Gut microbiota and major depressive disorder: A systematic review and meta-analysis”. Journal of Affective Disorders 266 (2020): 1-13.
10. Nikolova VL., et al. “Perturbations in gut Microbiota composition in psychiatric disorders: A review and meta-analysis: A review and meta-analysis”. JAMA Psychiatry12 (2021): 1343-1354.
11. Liu L., et al. “Gut microbiota and its metabolites in depression: from pathogenesis to treatment”. EBioMedicine104527 (104527): 104527.
12. Anand N., et al. “The role of gut dysbiosis in the pathophysiology of neuropsychiatric disorders”. Cells1 (2022).
13. Rukavishnikov G., et al. “Antimicrobial activity of antidepressants on normal gut microbiota: Results of the in vitro study”. Frontiers in Behavioral Neuroscience 17 (2023): 1132127.
14. González GM., et al. “Antidepressants with antimicrobial activity? A promising therapeutic strategy”. Medicine University3 (2022).
15. Sun Z., et al. “A review of neuroendocrine immune system abnormalities in IBS based on the brain-gut axis and research progress of acupuncture intervention”. Frontiers in Neuroscience 17 (2023): 934341.
16. Wang Y., et al. “Pathogenesis from the microbial-gut-brain axis in white matter injury in preterm infants: A review”. Frontiers in Integrative Neuroscience 17 (2023): 1051689.
17. Kim Y-K. “Neuroinflammation, gut-brain axis and immunity in neuropsychiatric disorders”. 1a edition. Singapur, Singapur: Springer (2023).
18. McIntyre RS. “Major Depressive Disorder”. Rong C, Subramaniapillai M, Lee Y, editors. Philadelphia, PA, United States of America: Elsevier - Health Sciences Division (2020).
19. Cangalaya C., et al. “Real-time mechanisms of exacerbated synaptic remodeling by microglia in acute models of systemic inflammation and tauopathy”. Brain, Behavior, and Immunity 110 (2023): 245-259.
20. Vu AP., et al. “Social isolation produces a sex- and brain region-specific alteration of microglia state”. European Journal of Neuroscience9 (2023): 1481-1497.
21. Hu H., et al. “Psychological stress induces depressive-like behavior associated with bone marrow-derived monocyte infiltration into the hippocampus independent of blood-brain barrier disruption”. Journal of Neuroinflammation1 (2022): 208.
22. Johnson D., et al. “A microbial-based approach to mental health: The potential of probiotics in the treatment of depression”. Nutrients6 (2023).
23. Rauf A., et al. “Neuroinflammatory markers: Key indicators in the pathology of neurodegenerative diseases”. Molecules10 (2022): 3194.
24. Baek S-H., et al. “Association between peripheral inflammatory cytokines and cognitive function in patients with first-episode schizophrenia”. Journal of Personalized Medicine7 (2022): 1137.
25. McKenzie R., et al. “Immunometabolic analysis of Mobiluncus mulieris and Eggerthella sp. Reveals novel insights into their pathogenic contributions to the hallmarks of bacterial vaginosis”. American Journal of Obstetrics and Gynecology2 (2022): 316.
26. Mohr AE., et al. “Lipopolysaccharide and the gut microbiota: considering structural variation”. FEBS Letters7 (2022): 849-875.
27. Ye X., et al. “Lipopolysaccharide induces neuroinflammation in microglia by activating the MTOR pathway and downregulating Vps34 to inhibit autophagosome formation”. Journal of Neuroinflammation1 (2020): 18.
28. Harsanyi S., et al. “Selected biomarkers of depression: What are the effects of cytokines and inflammation?” International Journal of Molecular Sciences1 (2022): 578.
29. Strandwitz P., et al. “GABA-modulating bacteria of the human gut microbiota”. Nature Microbiology3 (2019): 396-403.
30. Liu RT., et al. “Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials”. Neuroscience and Biobehavioral Reviews 102 (2019): 13-23.
31. Johnson D., et al. “Exploring the role and potential of probiotics in the field of mental health: Major depressive disorder”. Nutrients5 (2021): 1728.
32. Tian P., et al. “Multi-Probiotics ameliorate Major depressive disorder and accompanying gastrointestinal syndromes via serotonergic system regulation”. Journal of Advanced Research 45 (2023): 117-125.
33. Zheng Y., et al. “Probiotics fortify intestinal barrier function: a systematic review and meta-analysis of randomized trials”. Frontiers in Immunology 14 (2023): 1143548.
34. El Dib R., et al. “Probiotics for the treatment of depression and anxiety: A systematic review and meta-analysis of randomized controlled trials”. Clinical Nutrition ESPEN 45 (2021): 75-90.
35. Nikolova VL., et al. “Updated review and meta-analysis of probiotics for the treatment of clinical depression: Adjunctive vs. Stand-alone treatment”. Journal of Clinical Medicine4 (2021): 647.
36. Nikolova V., et al. “Gut feeling: randomized controlled trials of probiotics for the treatment of clinical depression: Systematic review and meta-analysis”. Therapeutic Advances in Psychopharmacology 9 (2019): 2045125319859963.